Roldán-Peña, Jesús M.

Link to this page

Authority KeyName Variants
14b77f03-dc06-4e48-92f2-d99933274fb9
  • Roldán-Peña, Jesús M. (1)
Projects

Author's Bibliography

Biotinylated selenocyanates: Potent and selective cytostatic agents

Roldán-Peña, Jesús M.; Puerta, Adrián; Dinić, Jelena; Jovanović Stojanov, Sofija; González-Bakker, Aday; Hicke, Francisco J.; Mishra, Atreyee; Piyasaengthong, Akkharadet; Maya, Inés; Walton, James W.; Pešić, Milica; Padrón, José M.; Fernández-Bolaños, José G.; López, Óscar

(Academic Press Inc., 2023)

TY  - JOUR
AU  - Roldán-Peña, Jesús M.
AU  - Puerta, Adrián
AU  - Dinić, Jelena
AU  - Jovanović Stojanov, Sofija
AU  - González-Bakker, Aday
AU  - Hicke, Francisco J.
AU  - Mishra, Atreyee
AU  - Piyasaengthong, Akkharadet
AU  - Maya, Inés
AU  - Walton, James W.
AU  - Pešić, Milica
AU  - Padrón, José M.
AU  - Fernández-Bolaños, José G.
AU  - López, Óscar
PY  - 2023
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0045206823000706
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5487
AB  - Most of the currently available cytotoxic agents for tackling cancer are devoid of selectivity, thus causing severe side-effects. This situation stimulated us to develop new antiproliferative agents with enhanced affinity towards tumour cells. We focused our attention on novel chalcogen-containing compounds (thiosemicarbazones, disulfides, selenoureas, thio- and selenocyanates), and particularly on selenium derivatives, as it has been documented that this kind of compounds might act as prodrugs releasing selenium-based reactive species on tumour cells. Particularly interesting in terms of potency and selectivity was a pharmacophore comprised by a selenocyanato-alkyl fragment connected to a p-phenylenediamine residue, where the nature of the second amino moiety (free, Boc-protected, enamine-protected) provided a wide variety of antiproliferative activities, ranging from the low micromolar to the nanomolar values. The optimized structure was in turn conjugated through a peptide linkage with biotin (vitamin B7), a cellular growth promoter, whose receptor is overexpressed in numerous cancer cells; the purpose was to develop a selective vector towards malignant cells. Such biotinylated derivative behaved as a very strong antiproliferative agent, achieving GI50 values in the low nM range for most of the tested cancer cells; moreover, it was featured with an outstanding selectivity, with GI50 > 100 µM against human fibroblasts. Mechanistic studies on the mode of inhibition of the biotinylated selenocyanate revealed (Annexin-V assay) a remarkable increase in the number of apoptotic cells compared to the control experiment; moreover, depolarization of the mitochondrial membrane was detected by flow cytometry analysis, and with fluorescent microscopy, what supports the apoptotic cell death. Prior to the apoptotic events, cytostatic effects were observed against SW1573 cells using label-free cell-living imaging; therefore, tumour cell division was prevented. Multidrug resistant cell lines exhibited a reduced sensitivity towards the biotinylated selenocyanate, probably due to its P-gp-mediated efflux. Remarkably, antiproliferative levels could be restored by co-administration with tariquidar, a P-gp inhibitor; this approach can, therefore, overcome multidrug resistance mediated by the P-gp efflux system.
PB  - Academic Press Inc.
T2  - Bioorganic Chemistry
T1  - Biotinylated selenocyanates: Potent and selective cytostatic agents
VL  - 133
DO  - 10.1016/j.bioorg.2023.106410
SP  - 106410
ER  - 
@article{
author = "Roldán-Peña, Jesús M. and Puerta, Adrián and Dinić, Jelena and Jovanović Stojanov, Sofija and González-Bakker, Aday and Hicke, Francisco J. and Mishra, Atreyee and Piyasaengthong, Akkharadet and Maya, Inés and Walton, James W. and Pešić, Milica and Padrón, José M. and Fernández-Bolaños, José G. and López, Óscar",
year = "2023",
abstract = "Most of the currently available cytotoxic agents for tackling cancer are devoid of selectivity, thus causing severe side-effects. This situation stimulated us to develop new antiproliferative agents with enhanced affinity towards tumour cells. We focused our attention on novel chalcogen-containing compounds (thiosemicarbazones, disulfides, selenoureas, thio- and selenocyanates), and particularly on selenium derivatives, as it has been documented that this kind of compounds might act as prodrugs releasing selenium-based reactive species on tumour cells. Particularly interesting in terms of potency and selectivity was a pharmacophore comprised by a selenocyanato-alkyl fragment connected to a p-phenylenediamine residue, where the nature of the second amino moiety (free, Boc-protected, enamine-protected) provided a wide variety of antiproliferative activities, ranging from the low micromolar to the nanomolar values. The optimized structure was in turn conjugated through a peptide linkage with biotin (vitamin B7), a cellular growth promoter, whose receptor is overexpressed in numerous cancer cells; the purpose was to develop a selective vector towards malignant cells. Such biotinylated derivative behaved as a very strong antiproliferative agent, achieving GI50 values in the low nM range for most of the tested cancer cells; moreover, it was featured with an outstanding selectivity, with GI50 > 100 µM against human fibroblasts. Mechanistic studies on the mode of inhibition of the biotinylated selenocyanate revealed (Annexin-V assay) a remarkable increase in the number of apoptotic cells compared to the control experiment; moreover, depolarization of the mitochondrial membrane was detected by flow cytometry analysis, and with fluorescent microscopy, what supports the apoptotic cell death. Prior to the apoptotic events, cytostatic effects were observed against SW1573 cells using label-free cell-living imaging; therefore, tumour cell division was prevented. Multidrug resistant cell lines exhibited a reduced sensitivity towards the biotinylated selenocyanate, probably due to its P-gp-mediated efflux. Remarkably, antiproliferative levels could be restored by co-administration with tariquidar, a P-gp inhibitor; this approach can, therefore, overcome multidrug resistance mediated by the P-gp efflux system.",
publisher = "Academic Press Inc.",
journal = "Bioorganic Chemistry",
title = "Biotinylated selenocyanates: Potent and selective cytostatic agents",
volume = "133",
doi = "10.1016/j.bioorg.2023.106410",
pages = "106410"
}
Roldán-Peña, J. M., Puerta, A., Dinić, J., Jovanović Stojanov, S., González-Bakker, A., Hicke, F. J., Mishra, A., Piyasaengthong, A., Maya, I., Walton, J. W., Pešić, M., Padrón, J. M., Fernández-Bolaños, J. G.,& López, Ó.. (2023). Biotinylated selenocyanates: Potent and selective cytostatic agents. in Bioorganic Chemistry
Academic Press Inc.., 133, 106410.
https://doi.org/10.1016/j.bioorg.2023.106410
Roldán-Peña JM, Puerta A, Dinić J, Jovanović Stojanov S, González-Bakker A, Hicke FJ, Mishra A, Piyasaengthong A, Maya I, Walton JW, Pešić M, Padrón JM, Fernández-Bolaños JG, López Ó. Biotinylated selenocyanates: Potent and selective cytostatic agents. in Bioorganic Chemistry. 2023;133:106410.
doi:10.1016/j.bioorg.2023.106410 .
Roldán-Peña, Jesús M., Puerta, Adrián, Dinić, Jelena, Jovanović Stojanov, Sofija, González-Bakker, Aday, Hicke, Francisco J., Mishra, Atreyee, Piyasaengthong, Akkharadet, Maya, Inés, Walton, James W., Pešić, Milica, Padrón, José M., Fernández-Bolaños, José G., López, Óscar, "Biotinylated selenocyanates: Potent and selective cytostatic agents" in Bioorganic Chemistry, 133 (2023):106410,
https://doi.org/10.1016/j.bioorg.2023.106410 . .
8
4
4